Dashboard
Manage Tickers

SAVA CASSAVA SCIENCES INC

Nasdaq cassavasciences.com


$ 4.43 $ 0.00 (0 %)    

Friday, 17-Oct-2025 07:16:34 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 597.07 $ 0.00 (0 %)
DIA $ 459.15 $ 0.00 (0 %)
SPY $ 658.71 $ 0.00 (0 %)
TLT $ 91.22 $ 0.00 (0 %)
GLD $ 397.83 $ 0.00 (0 %)
$ 4.52
$ 4.73
$ 4.42 x 50
$ 4.45 x 200
-- - --
$ 1.15 - $ 33.98
4,186,475
na
218.35M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-01-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 03-23-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 10-29-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 10-30-2018 09-30-2018 10-Q
29 07-26-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-06-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 04-26-2017 03-31-2017 10-Q
35 03-07-2017 12-31-2016 10-K
36 10-26-2016 09-30-2016 10-Q
37 07-19-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-03-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lucid-capital-markets-initiates-coverage-on-cassava-sciences-with-buy-rating-announces-price-target-of-8
LUCID CAPITAL MARKETS Initiates Coverage O...
10/06/2025 12:50:40

LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Cassava Sciences (NASDAQ:SAVA) with a Buy rating and announ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 17:06:52

cassava-sciences-sava-stock-is-surging-tuesday-whats-going-on
Cassava Sciences (SAVA) Stock Is Surging T...
09/23/2025 14:19:22

Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shar...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

why-super-league-enterprise-shares-are-trading-higher-by-200-here-are-20-stocks-moving-premarket
Why Super League Enterprise Shares Are Tra...
09/23/2025 09:41:19

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/22/2025 21:06:10

cassava-sciences-form4-filing-shows-ceo-richard-barry-bought-237941-shares-of-stock-at-an-average-price-of-225share
Cassava Sciences Form4 Filing Shows CEO Ri...
09/22/2025 20:22:59

- SEC Filing

cassava-sciences-q2-eps-092-down-from-013-yoy
Cassava Sciences Q2 EPS $(0.92) Down From ...
08/14/2025 11:35:38

Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.92) per share. This is a 807.69 percent decrease over earnings ...

cassava-sciences-reports-preclinical-results-of-a-study-evaluating-simufilam-in-a-well-accepted-mouse-model-of-tuberous-sclerosis-complex-tsc-related-epilepsy-first-clinical-study-for-simufilam-in-tsc-related-epilepsy-expected-to-begin-in-h1-2026
Cassava Sciences Reports Preclinical Resul...
08/04/2025 11:33:04

The Tsc1-CKO mice were treated with several doses of simufilam. Seizure activity was monitored for approximately three weeks af...

cassava-sciences-presented-a-poster-at-the-tsc-international-research-conference
Cassava Sciences Presented A Poster At The...
06/30/2025 11:02:08

The poster detailed two important observations that support Cassava's plan to initiate human clinical studies in H1 2026 to...

Core News & Articles
'FDA Clears First Blood Test Used In Diagn...
05/16/2025 17:32:57

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%...

cassava-sciences-q1-eps-048-down-from-043-yoy
Cassava Sciences Q1 EPS $(0.48) Down From ...
05/08/2025 12:14:14

Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.48) per share. This is a 11.63 percent decrease over losses of ...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
03/25/2025 17:05:55

hc-wainwright--co-reiterates-neutral-on-cassava-sciences-maintains-2-price-target
HC Wainwright & Co. Reiterates Neutral on ...
03/25/2025 15:40:19

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cassava Sciences (NASDAQ:SAVA) with a Neutral and maintains $2 ...

cassava-sciences-discontinues-developing-simufilam-for-alzheimers-after-another-phase-3-trial-flop
Cassava Sciences Discontinues Developing S...
03/25/2025 14:42:19

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus...

cassava-sciences-reports-topline-phase-3-refocus-alz-study-data
Cassava Sciences Reports Topline Phase 3 R...
03/25/2025 12:13:04

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in pat...

hc-wainwright--co-reiterates-neutral-on-cassava-sciencesto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
03/04/2025 17:23:59

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cassava Sciences (NASDAQ:SAVA) from Neutral to Neutral.

tesla-rebounds-while-tariffs-weigh-on-manufacturing-whats-driving-markets-monday
Tesla Rebounds While Tariffs Weigh On Manu...
03/03/2025 17:18:23

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digeste...

cassava-sciences-q4-2024-gaap-eps-057-beats-066-estimate-1286m-in-cash-and-cash-equivalents
Cassava Sciences Q4 2024 GAAP EPS $(0.57) ...
03/03/2025 12:32:52

Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0....

cassava-sciences-entered-into-an-agreement-with-yale-university-for-a-license-to-intellectual-property-rights-including-an-exclusive-license-to-an-issued-us-method-of-treatment-patent-for-simufilam-as-a-potential-treatment-for-seizures-related-to-rare-neurodevelopmental-disorders
Cassava Sciences Entered Into An Agreement...
02/27/2025 12:04:36

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION